Differential molecular mechanism of the docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells
Differential molecular mechanism of the docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells